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To report the acute and long-term results of ventricular tachycardia (VT) radiofrequency 37 catheter ablation (RFCA) as treatment for ES in patients with ARVC. 38
Methods 39
This multicenter study retrospectively enrolled 23 consecutive patients with ARVC (mean age 40 43.6±16.7 years; all male) who underwent 24 RFCA procedures for ES between 2003 and 41
42
Results 43 Thirteen (57%) patients had a previous VT RFCA;14 (61%) had right ventricular dysfunction 44 and 7 (30%) left ventricular ejection fraction ≤ 50%. The clinical VT was inducible in 19 45 (79%) procedures. Epicardial ablation was performed in 4 (17%) procedures. The median 46 number of targeted VTs was 1 [1] [2] [3] [4] [5] [6] . Complete acute success (no VT inducible) was achieved 47 in 11 (46%) procedures and partial acute success (clinical VT nor inducible) in 11 (46%). 48
After a median follow-up of 3.9 years [1 month-10 years], ES recurred in 2 patients and end-49 stage heart failure developed in 4 (17%), leading to 1 death and 3 heart transplantations. year follow-up, the probability of freedom from VT recurrence was 75% and did not 51 significantly predict long-term survival. At last evaluation, 8 (35%) patients were free of non-52 beta-blocker anti-arrhythmic drugs as compared with 1 (4%) at baseline (p = 0.02). 53
Conclusion 54
Catheter ablation was efficient to prevent ES recurrence in patients with ARVC. However, 55
Introduction 58 59 Arrhythmogenic right ventricular cardiomyopathy (ARVC), a type of arrhythmogenic 60 cardiomyopathy is a rare inherited disease associated with progressive fibrofatty myocardial 61 remodeling affecting mostly the right ventricle (RV) 1, 2 . Structural alterations associated with 62 ARVC predispose to reentrant ventricular tachycardia (VT), and patients may experience a 63 high burden, especially those at advanced disease stage 3 . Implantable cardioverter-64 defibrillators (ICDs) can efficiently prevent sudden cardiac death; however, VT events among 65 ICD carriers with ARVC are frequent and are associated with ICD firing and increased 66 cardiovascular morbidity 3 . 67
Electrical storm (ES) is a life-threatening complication of structural heart diseases 68 associated with advanced disease stage, with poor short-and long-term prognosis, that 69 requires specific therapeutic interventions 4,5 . Patients with ARVC may experience ES, but the 70 clinical implications and prognostic significance in this setting are less well understood. 71
Multiple studies have demonstrated a benefit of radiofrequency catheter ablation 72 (RFCA) for treating ARVC-associated VT [6] [7] [8] , which is therefore recommended in addition to 73 ICD 9,2 . Several reports also suggest that RFCA is effective in reducing the ventricular 74 arrhythmia burden in the context of ES, when evaluated in various heart diseases 4,10 . 75
However, the benefits of RFCA as a treatment for ES in ARVC has not been specifically 76 assessed. In this multicenter observational study, we analyzed the clinical and 77 electrophysiological characteristics of ARVC-related ES and report the outcomes of RFCA. 
Patients and definitions 83
Patients who underwent catheter ablation for ES from 2003 to 2015 in 7 tertiary care French 84 centers were retrospectively included (n=23) if they 1) had a definite diagnosis of ARVC 85 according to the 2010 revised Task Force Criteria (TFC) 11 ; 2) presented ES defined by at least 86 3 separate sustained VT episodes or ventricular fibrillation episodes within 24 hr, documented 87 by 12-lead electrocardiography (ECG), Holter monitoring or ICD interrogation; 3) and were 88 referred for radiofrequency ablation as an urgent treatment for ES. Any ICD therapy 89 (antitachycardia pacing or shock) was considered a sustained VT episode. In cases of 90 unsuccessful antitachycardia pacing or shock, further therapies related to the same episode 91
were not counted as an individual VT episode. 92
Patient screening involved reviewing all consecutive VT RFCA procedures in each 93 center during the inclusion period, identifying those performed for ARVC-related VT (n=121 94 across the 7 centers), and selecting procedures that were specifically performed as urgent 95 treatment for ES in the days or weeks after ES. 96 ARVC was prospectively diagnosed according to the current consensus documents 97 and was retrospectively assessed for final diagnosis according to the 2010 revised TFC 11 at 98 the time of data collection. The TFC criteria regarding the arrhythmia refer to an evaluation 99 before the ES event. 
Follow-up and endpoints 139
Patients were followed routinely by their treating electrophysiologist or cardiologist. VT 140 recurrence was defined as the recurrence of any documented sustained VT lasting ≥ 30 sec or 141 any appropriate ICD therapy including anti-tachycardia pacing. Recurrence of ES followed 142 the same definition as for the initial presentation. Medical records and stored electrograms 143 from ICD interrogations were reviewed at each center to identify VT recurrence and assess 144 ICD therapies. 145
Data collection 146
Data regarding demographics, medical history, clinical evaluation, 12-lead ECG, genetic 147 analyses, echocardiography and computed tomography imaging, ICD interrogations, 148 electrophysiology studies and catheter ablation procedures were retrieved from medical 149 records at each center. 150
Statistical analyses 151
Continuous data are reported as mean ± SD or median [ whereas multiple sustained monomorphic VTs could be induced by ventricular programmed 183 stimulation in 15 (63%) procedures (Table 2 and Supplementary Table 2 for 
Long-term outcomes 201
During a median follow-up of 3.9 years (range 1 month-10 years), ES recurred in 2 patients 202 (see Supplementary Table 3 for detailed individual outcomes). The first patient underwent 203 redo RFCA for ES at 2.5 years after the initial procedure but died 2.8 years later in the post-204 operative course of heart transplantation (HT) that was performed for end-stage heart failure. 205
The other had ES recurrence 1.5 years after the initial ES; he underwent redo RFCA and 206 remained free of VA recurrence in a subsequent follow-up period of 1 year. The cumulative 207 probability of freedom from ES recurrence at 1 and 5 years after the initial ES RFCA 208 procedure was 100% and 85% ( Figure 1A & Supplementary Table 4 for 95% CIs of survival 209 rates). Six patients had VT recurrence during follow-up. All VT recurrences were 210 monomorphic and triggered appropriate ICD therapies (details in Supplementary Table 3 ). 211
Five patients underwent redo VT ablation, including 4 who remained free of VT recurrence at 212 the end of follow-up. The cumulative probability of freedom from VT recurrence at 1 and 5 213 years after the initial ES RFCA procedure was 77% and 66% ( Figure 1B ). Complete acute 214 procedural success was not significantly associated with freedom from VT recurrence after 215 the initial ES ablation procedure (HR = 0.27, 95% CI [0.05-1.43], p = 0.13). Baseline LVEF 216 and presence of RV systolic dysfunction were not associated with VT recurrence. After the 217 initial ES catheter ablation procedure, 4 patients had ICD placement, so all patients had an 218 ICD during follow-up. At the end of follow-up, 8 (35%) patients were not taking non-beta-219 blocker anti-arrhythmic agents as compared with 1 (4%) at baseline (p = 0.02). 220
Three patients died during follow-up (2 immediately after HT and 1 from hemorrhagic 221 stroke while awaiting HT) and 1 patient survived HT. These 4 patients had end-stage heart 222 failure related to ARVC with severe biventricular systolic dysfunction. The cumulative 223 probability of survival without death or HT at 1 and 5 years after initial ES catheter ablation 224 was 90% and 84% (Figure 2A ). Neither VT recurrence during follow-up (HR 2.32, 95% CI 225 [0.32-16.74], p = 0.40) ( Figure 2B ) nor complete acute procedural success (HR 0.96, 95% CI 226 [0.13-6.86], p = 0.97) was significantly associated with death or heart transplantation during 227 follow-up, Among the 4 patients who died or underwent HT, 2 did not show VA recurrence 228 after the initial RFCA. Baseline LVEF was significantly associated with risk of death or HT 229 12 (HR for a 1% LVEF increase: 0.90, 95% CI [0.81-60.99], p = 0.045) ( Figure 2C ). The 230 detailed course of adverse events during follow-up is in Supplementary Table 3.  231   232   Discussion  233 234 This is the first study to report outcomes after RFCA performed for ES in patients with 235 ARVC. RFCA was safe and effective to prevent ES recurrence, with no periprocedural 236 adverse outcomes and only 2 ES recurrences. In addition, 1) patients presenting ES frequently 237 had ARVC with overt RV structural alterations and a significant history of ventricular 238 arrhythmias with previous VT ablations, 2) usually one monomorphic VT was responsible for 239 the ES event, 3) complete procedural success was achieved in 11 (46%) procedures and 240 elimination of the clinical VT could be achieved in 22 (92%), 4) the 5-year estimated VT 241 recurrence rate was 34%, and 5) we found a 24% 5-year estimated rate of mortality or HT 242 after an ES eventmortality consecutive to heart failure related to ARVC structural 243 dysfunction and that was not associated with the long-term arrhythmic outcome after RFCA. 244
245

Clinical features associated with ES in ARVC 246
In our series of ARVC patients presenting ES and referred for RFCA, we found a high 247 prevalence of electrical and structural abnormalities as compared with large cohorts of ARVC 248 patients 12,13 . Most patients had severe RV systolic dysfunction, 35% had LV dysfunction, 249
43% showing epsilon-wave and 53% previous VT RFCA. All were male, and the mean age at 250 ES was 43.6 years, when most ARVC patients are symptomatic 14 . Overall, 66% of screened 251 individuals had a pathologic mutation in desmosomal genes, which is higher than what is 252 usually found in ARVC cohorts and associated with worse prognosis 12 . These high-risk 253 features were also more frequent than in a recent large cohort of ICD carriers 15 . However, 254 13 patient characteristics were overall comparable to studies enrolling ARVC patients 255 undergoing VT ablation 8, 16 , except in terms of the frequency of ECG depolarization 256 abnormalities and previous VT ablation, which were more frequent in our patients and 257 suggests that ARVC patients experiencing ES have a more extensive electrical substrate than 258 those with isolated VT. 259
The study of Carbuciccio et al. reported outcomes of ES ablation among 95 patients 260 (76% with ischemic cardiomyopathy and 13 [14%] with ARVC] 10 . Mean age was higher than 261 in our series (64±13 years), 38% of patients had several clinical VTs and 11% required 262 periprocedural hemodynamical support. In our ARVC series, a single VT was responsible for 263 most of the ES; we did not observe any patient with repetitive polymorphic VT; and only 1 264 patient had > 5 inducible VTs. Hemodynamic instability was rare, which is probably related 265 to the conserved or mildly impaired LV function in most ARVC patients. 266
267
Procedural outcomes 268
We report a relatively low rate of complete acute procedural success, 46%, as compared with 269 the 72% in the largest series of ES ablation 10 
Long-term survival after ES in ARVC 300
ES is an independent predictor of death among various heart diseases 5 . However, the 301 mechanisms by which ES leads to increased mortality remain poorly understood, and its 302 clinical significance in ARVC as compared with other heart diseases is poorly established. In 303 a recent meta-analysis of 471 ES patients from 39 publications, only 22 had ARVC, which 304 15 precluded generalizing findings to patients with ARVC 4 . A key question is whether RFCA 305 improves long-term survival after an ES event in ARVC, or if RFCA only permits a palliative 306 benefit of alleviating the VT burden. In the study of Carbuciccio et al., long-term survival 307 was worse for patients for whom RFCA resulted in partial success or procedural failure, with 308 a significant occurrence of sudden cardiac death related to untractable ES recurrence 10 . In the 309 above-mentioned meta-analysis, arrhythmic sudden death accounted for 23% of long-term 310 mortality 4 . These findings suggest that VA recurrence after RFCA for ES contributes to 311 survival to some extent. In our study specifically addressing ARVC, we found no association 312 between long-term survival and procedural success or VT/VF recurrence during follow-up. 313
Fatal outcomes were all related to ARVC-related structural dysfunction, and we found no 314 temporal association between VT recurrence and mortality or HT. These results are in line 315 with a recent multicenter observational study finding no difference in survival in RFCA-316 versus AAD-treated patients despite a significantly reduced VT burden in the former group 22 . 317 Also, a prospective study including patients with ES occurring in various forms of 318 cardiomyopathies showed that patients with ES shared many similarities with those 319 presenting severe decompensated heart failure and a comparable prognosis 23 . ES clinical 320 presentation and accessibility to RFCA seems more favorable in ARVC than in the overall ES 321 landscape, but eliminating the arrhythmic substrate responsible for ES may have little impact 322 on the progressive structural deterioration. For ARVC patients with advanced disease, ES 323 might be considered an epiphenomenon of disease progression toward end-stage heart failure. 324 325
Limitations 326
The main limitations of our study are its retrospective nature and the long inclusion period. 327
The low number of included patients over a 12-year inclusion period in a specialized center 328 certainly does not reflect the ES incidence in ARVC, data that would have been interesting to 329 16 report but given the nature of our study, cannot be provided. The patient screening 330 methodology that we used identified patients who underwent VT ablation specifically for ES 331 treatment and not those who were managed medically. A recent retrospective study of 31 ICD 332 carriers reported an annual incidence of ES of 31% 24 , so the definition of ES itself 333 encompasses diverse and arrhythmia profiles that range from 3 separate episodes of well-334 tolerated VT to the critical situation of incessant VT, which was the most frequent scenario in 335 our study. The RFCA strategies and techniques were heterogenous, considering that they 336 were performed in 7 different centers over 12 years, beginning in 2003. Much progress has 337 been made in the field of VT ablation over the last decade, including refinement of 338 electroanatomic mapping, substrate identification and epicardial ablation; therefore, our acute 339 and late results might have been improved if RFCA procedures were performed in a 340 contemporary setting. Also, we lack quantitative data regarding ICD data at baseline and 341 during follow-up, which would have been helpful to assess the reduction in VT burden 342 provided by RFCA. Finally, the small study population warrants caution in interpreting 343 descriptive and survival statistics. 
